Rheumatology: Long-term (5+ years) safety profile for selective Janus kinase (JAK1/JAK2) inhibitor baricitinib in patients with moderate to severe active rheumatoid arthritis (RA) reported

http://www.jrheum.org/content/early/2018/09/09/jrheum.171361